Search tips
Search criteria 


Logo of onclettLink to Publisher's site
Oncol Lett. 2017 March; 13(3): 1789–1796.
Published online 2017 January 26. doi:  10.3892/ol.2017.5654
PMCID: PMC5403669

miR-600 inhibits cell proliferation, migration and invasion by targeting p53 in mutant p53-expressing human colorectal cancer cell lines


Mutations of the tumor protein p53 gene, a tumor suppressor, are one of the most frequent genetic alterations observed in cancer. It has been reported that mutations in p53 result in the loss of wild-type p53 activity, and the gain of novel oncogenic properties that promote tumor growth and progression. Recent studies have demonstrated that a number of microRNAs (miRs) are involved in the post-transcriptional regulation of p53. The present study demonstrates that miR-600 is a direct negative regulator of p53 through binding a site in the 3′ untranslated region of p53 mRNA in human colorectal cancer (CRC) cells. Overexpression of miR-600 by lentiviral-mediated transduction decreased endogenous levels of p53 protein and inhibited cell proliferation, migration and invasion in mutant p53-expressing human CRC cell lines (SW480, SW620 and DLD-1) in vitro. In addition, silencing of p53 with small interfering RNA led to a similar phenotype. Furthermore, overexpression of miR-600 or p53 knockdown suppressed the expression of matrix metalloproteinase 9, and promoted the expression of E-cadherin and β-catenin. The results of the current study demonstrate that miR-600 is an important negative regulator of p53, and suggest that targeting mutant p53 using lentiviral-mediated miR-600 overexpression is a promising therapeutic strategy for the treatment of CRCs with p53 mutations.

Keywords: microRNA-600, mutant p53, lentiviral vector, colorectal cancer, migration, invasion


Colorectal cancer (CRC) is the third most common cancer worldwide, and is a major cause of morbidity and mortality (1). Specifically, CRC is the third most frequent cancer observed in males and the second most frequent cancer in females (2). CRC represents ~9% of all cancer cases (3). Diagnosis of and therapy for CRC have advanced significantly over the last ten years; however, 5-year survival rates remain poor (4). Therefore, there is a requirement for the development of novel therapeutic agents with a high efficacy for the treatment of CRC.

The tumor suppressor protein p53, encoded by the tumor protein p53 (TP53) gene, prevents the development and progression of cancer through regulation of a range of cellular mechanisms, including apoptosis, cell cycle arrest, metabolism and DNA repair (5,6). In total ~50% of all human cancers have mutations in TP53 that lead to the production of functionally inactive p53 (79). In addition, these mutations frequently induce tumor-promoting actions through dominant-negative inactivation of the remaining wild-type TP53 allele, or apoptosis resistance, increased tumor aggressiveness and metastatic potential (6,10,11). Furthermore, gain-of-function TP53 mutations may produce mutant p53 protein, which exhibits oncogenic effects, including increased cell proliferation, invasion, metastasis and drug resistance, and inhibition of apoptosis (12).

A previous study demonstrated that p53 is able to regulate the expression of specific microRNAs (miRs), which contributes to tumor suppression by controlling the expression of the targets of these miRs, which include key effectors of numerous cellular processes, for example cell cycle progression, epithelial-mesenchymal transition, stemness, metabolism, cell survival and angiogenesis (13). Reciprocally, the activity of p53 has been observed to be under the control of several miRNAs, including miR-125 and miR-504, which were identified to negatively regulate p53 expression by directly targeting the 3′untranslated region (UTR) of TP53 (14,15). In addition, previous studies have reported that several miRNAs (miR-29, miR-34a, miR-122, miR-192, miR-194 and miR-215) positively regulate p53 expression (1621). miRs are short non-coding RNAs of between 18 and 24 nucleotides in length, which participate in numerous biological pathways through regulating the post-transcriptional expression of genes (22). In total ~1,400 miRs have been identified in humans thus far, and miRs have been demonstrated to serve important roles in the pathogenesis of disease (23). For example, miRs have been reported to regulate the expression of their target mRNAs to affect tumor growth, invasion and angiogenesis in cancer (24,25).

In the present study, bioinformatic analysis, performed using TargetScan Software (version 6.2;, identified that the 3′UTR of p53 mRNA contains a putative miR-600 binding site. Subsequent ectopic overexpression of miR-600 in vitro using lentiviral-mediated transduction was observed to decrease cell proliferation, migration and invasion in mutant p53-expressing human CRC cell lines, indicating that miR-600 targets p53 mRNA for degradation in this context. Furthermore, overexpression of miR-600 inhibited the expression of matrix metalloproteinase 9 (MMP-9) and promoted the expression of E-cadherin and β-catenin proteins. Similar results were obtained when p53 expression was silenced using small interfering RNA (siRNA). These results suggest that targeting the miR-600/p53 network may lead to the identification of novel therapeutic agents for the treatment of CRC.

Materials and methods

Cell culture

Human CRC cell lines (SW480, SW620 and DLD-1) and human embryonic kidney cells (HEK293T) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). SW480 and DLD-1 cells were cultured in RPMI-1640 medium, and SW620 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (both Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). All media was supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin and streptomycin (both Invitrogen; Thermo Fisher Scientific, Inc.). All cells were maintained at 37°C in an incubator with 5% CO2.

siRNA transfection

A siRNA was designed to target the human p53 gene based on the public GenBank sequence ( and was purchased from GenePharma Co., Ltd. (Shanghai, China). The sequence of p53 siRNA was 5′-GACUCCAGUGGUAAUCUAC-3′. The sequence of scramble siRNA (control) was 5′-GCAACGGCAUUCCACCUUU-3′. SW620, SW480 and DLD-1 cells (2×104 cells/well) were seeded into 6-well plates and were transfected with 50 µM scramble siRNA [Negative control (NC)] or p53-siRNA using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

Lentiviral vector construction for miR-600 overexpression

Hsa-miR-600 sequence was obtained from miRBase database ( For the construction of the lentiviral vector expressing miR-600, miR-600 precursors and their native context sequences (upstream and downstream flanking genomic sequences) were amplified from HEK293T cell genomic DNA using polymerase chain reaction (PCR) with the Takara Ex Taq™ Hot Start Version kit (Takara Bio, Inc., Otsu, Japan). The PCR reaction conditions were as follows: 94°C for 5 min, followed by 94°C for 45 sec, 60°C for 45 sec and 72°C for 1 min, for a total of 30 cycles; a final step at 72°C for 10 min was subsequently performed. The following primers were used for PCR: Forward-SalI, 5′-gcggtcgacTACTCCTTGATCCATTTCCAT-3′; and reverse-EcoRI, 5′-ggaattcaaaaaGGAACACTTCTTGCATTGTCT-3′ (uppercase letters indicate the coding primer sequence; lowercase letters refer to the enzyme loci and the protective bases). The resulting PCR product was digested with SalI and EcoRI prior to insertion into a human U6 promoter-containing pBluescript SK (+) plasmid. The construct obtained was then digested with SalI and EcoRI, then U6 promoter and subsequent pre-miR-600 genomic fragments were cloned into the lentiviral plasmid pLUNIG as previously described (26,27). A lentiviral vector expressing a short hairpin (sh) RNA targeting firefly luciferase (shLuc target sequence, 5′-TGCGCTGCTGGTGCCAACCCTATTCT-3′) was used as the control, as previously described (26,27). Vesicular stomatitis virus GP pseudotyped lentiviruses were produced by co-transducing HEK293T cells with lentivirus expression and packaging plasmids (pMD2.G, pMDL-G/P-RRE and pRSV-REV). A total of 5×104 CRC cells (SW480, SW620 or DLD-1) were then transduced with the lentiviruses (lentiviral vector expressing miR-600 or control) in the presence of 8 µg/ml Polybrene (Sigma-Aldrich; EMD Millipore, Billerica, MA, USA).

Cell viability assay

Cell viability was measured using the MTT assay. Briefly, cells were seeded into 96-well plates at a density of 2×103 cells/well and cultured at 37°C for 1, 2, 3 or 4 days. At these time points, 20 µl of MTT (5 mg/ml) solution was added to each well and cells were incubated for an additional 4 h at 37°C. The formazan product was dissolved with dimethyl sulfoxide and plates were incubated for 10 min at room temperature. A microplate reader was subsequently used to measure the absorbance at 490 nm. Each condition was determined in quintuplicate, and all experiments were repeated ≥3 times.

Cell migration and invasion assays

In vitro cell migration and invasion assays were performed in 24-well Transwell cell culture chambers with 8 µm pores (Costar; Corning Incorporated, Cambridge, MA, USA) according to the manufacturer's instructions. For the migration assay, DLD-1, SW480 and SW620 cells in starvation medium (without FBS) (2.5×105/100 µl) were seeded into the Transwell filter membrane chambers and incubated at 37°C for 16, 24 or 48 h, respectively. The appropriate culture medium supplemented with 10% FBS was added to the lower chambers as a chemoattractant. Following incubation, cells in the lower chambers were fixed using 4% paraformaldehyde and stained with 0.1% crystal violet solution. Cells that did not migrate were removed from the upper chamber surface using a cotton swab, and the number of cells that migrated to the lower chamber was counted in ≥5 fields (fields were randomly selected under a light microscope at magnification, ×20). For the invasion assay, Transwell membranes were pre-coated with 10 µl of Matrigel (diluted 1:3; BD Biosciences, San Jose, CA, USA) prior to the process described above.

Western blot analysis

Cells were lysed in a radioimmunoprecipitation assay lysis buffer (Sigma-Aldrich; EMD Millipore) containing a protease inhibitor cocktail (Thermo Fisher Scientific, Inc.). The total concentration of protein obtained was measured using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Total protein (30 µg) was separated by SDS-PAGE using an 8 or 12% gel and subsequently transferred onto polyvinylidene difluoride membranes (EMD Millipore). Membranes were blocked in 5% skimmed milk (BD Biosciences) for 1 h at room temperature and incubated with primary antibodies overnight at 4°C. Subsequently, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Antibody binding was detected using an enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The following primary antibodies were used: Mouse anti-E-cadherin (diluted 1:3,000; #610181; BD Biosciences) and anti-vimentin (diluted 1:3,000; #5550513; BD Biosciences), rabbit anti-p53 (diluted 1:500; ab31333; Abcam, Cambridge, UK), rabbit anti-Slug (diluted 1:1,000; #9585) and anti-β-actin (diluted 1:1,000; #4970, Cell Signaling Technology, Inc., Danvers, MA, USA), mouse anti-fibronectin (diluted 1:100; SC18825) and anti-β-catenin (diluted 1:100; SC7199; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and rabbit anti-MMP-9 (diluted 1:1,000; BS1241; Bioworld Technology, Inc., St. Louis Park, MN, USA). The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit (diluted 1:2,000; ab6721; Abcam) or rabbit anti-mouse (diluted 1:2,000; ab6728; Abcam) secondary antibody.

Dual-luciferase reporter assay

Putative targets of miR-600 were predicted using TargetScan Software (version 6.2; DNA fragments corresponding to the 3′UTR of TP53 mRNA containing the putative miR-600 binding site (wt-P53-3′UTR-sense with SpeI site, 5′-CTAGTTACTGTGAGGGATGTTTGGGAGATGTAAGAAATGTTCTTGA-3′ and wt-P53-3′UTR-antisense with HindIII site, 5′-AGCTTCAAGAACATTTCTTACATCTCCCAAACATCCCTCACAGTAA-3′), or a mutated version of this site (mut-P53-3′UTR-sense with SpeI site, 5′-CTAGTTACTGTGAGGGATGTTTGGGAGATAGACGAAATGTTCTTGA-3′ and mut-P53-3′UTR-antisense with HindIII site, 5′-AGCTTCAAGAACATTTCGTCTATCTCCCAAACATCCCTCACAGTAA-3′), were chemically synthesized and cloned into the SpeI and HindIII sites of pMIR-REPORT luciferase vector (Thermo Fisher Scientific, Inc.). HEK293T cells were seeded into a 24-well plate at a density of 3×105 cells/well and co-transduced with pMIR-REPORT-wt-P53-3′UTR or pMIR-REPORT-mut-P53-3′UTR and miR-600 expression plasmids, and a Renilla plasmid (RLSV40; Promega Corporation, Madison, WI, USA) as internal normalization. Cells were cultured at 37°C in an incubator with 5% CO2 for 48 h, and then cells were lysed using Passive Lysis Buffer (Promega Corporation). Luciferase activity was detected using the Dual-Luciferase Reporter Assay kit (Promega Corporation) according to the manufacturer's instructions. Results were obtained from three independent repeats.

Statistical analysis

One-way analysis of variance (ANOVA) and Student's t-test were used to statistically compare differences between groups. Post-hoc tests (Student-Newman-Keuls method) were used following performance of ANOVA. Statistical analysis was performed using SPSS software (version 15.0; SPSS, Inc., Chicago, IL, USA). Results are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.


miR-600 reduces CRC cell viability, migration and invasion in vitro

To investigate the effects of miR-600 on CRC cell growth, migration and invasion, SW480, SW620 and DLD-1 cells were transduced with lentiviral vectors expressing miR-600 or the control. The MTT assay was performed to determine cell viability (Fig. 1). As shown in Fig. 1A, the viability of SW480 cells transduced with miR-600-containing lentivirus was significantly suppressed compared with the control group 3 and 4 days following transduction (P<0.0001). Similar results were observed in SW620 and DLD-1 cells 3 and 4 days post-transduction (P<0.0001 vs. the control group; Fig. 1A). The impact of miR-600 overexpression on cell migration and invasion abilities was measured using Transwell assays in vitro. This identified that miR-600 overexpression significantly decreased migration and invasion abilities of SW480 (P<0.0001; Fig. 1B), SW620 (P<0.0001; Fig. 1C) and DLD-1 (migration, P=0.0008 and invasion, P=0.0001, Fig. 1D) cells compared with the control group. These results suggest that the overexpression of miR-600 inhibits proliferation, migration and invasion in human CRC cells.

Figure 1.
Ectopic overexpression of miR-600 through lentiviral-mediated transduction inhibits CRC cell proliferation, migration and invasion in vitro. (A) Effect of miR-600 overexpression on the viability of CRC cell lines SW480, SW620 and DLD-1. Effect of miR-600 ...

p53 is a direct target of miR-600 in CRC cells

To identify the molecular target involved in miR-600 regulation of CRC cell proliferation, migration and invasion, the effects of mutant p53 protein expression were investigated in CRC cells. As shown in Fig. 2A, overexpression of miR-600 by lentiviral-mediated transduction inhibited p53 protein expression in SW480, SW620 and DLD-1 CRC cells. To further investigate whether p53 is a direct target of miR-600, bioinformatic analysis was performed using TargetScan software. This revealed a putative miR-600 binding site in the 3′UTR of p53 mRNA (Fig. 2B).

Figure 2.
miR-600 influences the expression of EMT-associated proteins by targeting p53 in mutant p53-expressing human CRC cell lines. (A) Western blotting revealed that overexpression of miR-600 through lentiviral-mediated transduction inhibited p53 protein expression ...

A luciferase reporter assay was subsequently performed to determine whether miR-600 directly targeted the 3′UTR of p53 mRNA in vitro. A fragment of the 3′UTR of p53 with a wild-type or mutant miR-600 target binding site was cloned into the pMIR-REPORT luciferase reporter vector. The results of the dual-luciferase reporter assay demonstrated that miR-600 significantly suppressed luciferase reporter activity at the wild-type p53 3′UTR site (P=0.0044 vs. the control group), whereas mutation of the miR-600 binding site blocked this suppressive effect (P=0.0014 vs. wild-type site; Fig. 2C). These results indicate that miR-600 directly targets the 3′UTR of p53 mRNA to downregulate the expression of p53 protein.

miR-600 modulates epithelial-mesenchymal transition (EMT)-associated protein expression by targeting p53 mRNA in mutant p53-expressing human CRC cell lines

The expression levels of proteins associated with EMT proteins were detected through western blotting (Fig. 2D). Levels of the epithelial cell marker proteins E-cadherin and β-catenin, were increased in CRC cell lines (SW480, SW620 and DLD-1) overexpressing miR-600. In addition, protein levels of MMP-9, a member of the MMP family, appeared to be decreased in CRC cells overexpressing miR-600.

siRNA silencing of mutant p53 expression reduces cell viability, migration and invasion in mutant p53-expressing human CRC cell lines

The effects of p53 mutation on CRC cell viability, migration and invasion were further investigated in vitro using the MTT assay, and Transwell migration and invasion assays, respectively. These assays demonstrated that knockdown of mutant p53 expression in SW480, SW620 and DLD-1 cells significantly decreased cell viability compared with the control group at 3 and 4 days post-transfection (P<0.001; Fig. 3A). In addition, the knockdown of mutant p53 expression in SW480 cells significantly reduced cell migration (91.6%) and invasion (75.6%) abilities (P<0.0001 vs. the control group; Fig. 3B). Similarly, migration and invasion were decreased by 79.3% (P=0.0003) and 84.2% (P=0.0019), respectively, in SW620 cells (Fig. 3C), and 78.9% (P<0.0001) and 72.2% (P=0.0003), respectively, in DLD-1 cells (P<0.001; Fig. 3D) compared with the control group. These results indicate that knockdown of mutant p53 expression in CRC cells reduces their viability, and inhibits their ability to migrate and invade.

Figure 3.
siRNA silencing of p53 expression inhibits colorectal cancer cell proliferation, migration and invasion. (A) The MTT assay was performed to determine the viability of SW480, SW620 and DLD-1 cells transfected with Sip53. A total of 50 µM negative ...

siRNA silencing of mutant p53 expression inhibits the expression of MMP-9 and promotes the expression of epithelial cell markers in mutant p53-expressing human CRC cell lines

To evaluate the effect of p53 on the E-cadherin, β-catenin and MMP-9 protein expression, p53-specific (sip53) and negative control (NC) siRNAs were transfected into mutant p53-expressing CRC cell lines (SW480, SW620 and DLD-1). The results demonstrate that p53 protein expression was markedly decreased 48 h following siRNA transfection in all cell lines compared with the cells transfected with the negative control (Fig. 4). Simultaneously, MMP-9 protein expression was decreased, while E-cadherin and β-catenin protein expression was increased in SW480 (Fig. 4A), SW620 (Fig. 4B) and DLD-1 (Fig. 4C) cells transfected with siRNA compared with the negative control cells.

Figure 4.
siRNA silencing of p53 expression modulates epithelial-mesenchymal transition-associated protein expression in mutant p53-expressing human colorectal cancer cell lines. Western blot showing the expression of p53, MMP-9, E-cadherin, β-catenin and ...


Mutation of TP53 is one of the most frequent genetic alterations in all cancer types, including CRC (28). Although mutation of TP53 may lead to loss of wild-type p53 activity, some mutated forms of p53 may result in the gain of oncogenic properties that promote tumor growth and progression (29). The ability of mutant p53 to drive enhanced cell growth, invasion and motility has been confirmed in vitro and in xenograft models (2832). Previous studies have demonstrated that when endogenous expression of mutant p53 was knocked out, the proliferative capacity and chemoresistance of a number of human cancer cell lines decreased, while in nude mice tumorigenicity was also reduced (33,34). In total, ~50% of all human cancer is caused by p53 mutations (35).

Previous studies have indicated that miRs have important roles in the pathogenesis of cancer, including the regulation of tumor proliferation, invasion, metastasis and angiogenesis through altering the expression levels of target mRNAs (24,25). It has been reported that ≥1,000 miRs are found in the human genome and that the expression ~30% of the human genome is regulated by miRs (36), highlighting the possibility of the existence of a specific miR that directly regulates p53 protein expression and its subsequent function. In the present study, miR-600 was identified as a direct negative regulator of p53 through its binding to the 3′UTR of p53 mRNA. In addition, it was demonstrated that overexpression of miR-600 repressed the endogenous level of p53 protein and inhibited cell proliferation, migration and invasion in mutant p53-expressing human CRC cell lines (SW480, SW620 and DLD-1) in vitro. Knockdown of endogenous mutant p53 by siRNA has been reported to reduce cell growth and chemoresistance in vitro in a number of human cancer cell lines, and inhibit tumor growth in nude mice (33,34). Furthermore, silencing of mutant p53 by siRNA was able to induce cell cycle arrest and apoptosis in human prostate (37) and bladder cancer (38) cells. In the present study, siRNA silencing of p53 produced a similar phenotype to miR-600 overexpression in SW480, SW620 and DLD-1 cells.

MMP family proteins are associated with cardiovascular disease and cancer metastasis, and regulated by p53 (39). It has been reported that wild-type p53 is able to suppress the expression of MMP-9 (40,41). However, a number of mutant p53 proteins do not possess this ability. Prior research has revealed that MMP-9 is able to reduce the expression of E-cadherin (42). In the current study, overexpression of miR-600 and p53 knockdown were observed to suppress MMP-9 expression, and promote the expression of E-cadherin and β-catenin proteins. E-cadherin and β-catenin are important for epithelial cell-cell adhesion in the normal epithelium (43). Loss of E-cadherin is an important event in EMT during tumorigenesis (44). A previous study identified that mutant p53 downregulated E-cadherin expression in the CRC cell line HCT116 (44). Dong et al (45) reported that mutant gain-of-function p53 induces EMT through modulation of the miR-130b-zinc finger E-box binding homeobox 1 axis in endometrial cancer cells. The current study observed that inhibition of mutant p53 expression, through overexpression of miR-600 or by siRNA silencing of mutant p53, induced E-cadherin expression in mutant p53-expressing human CRC cell lines.

In conclusion, the present study identified that miR-600 is a direct negative regulator of p53. Overexpression of miR-600 or siRNA silencing of mutant p53 were observed to inhibit proliferation, migration and invasion, suppress MMP-9 expression, and promote the expression of E-cadherin and β-catenin in mutant p53-expressing human CRC cell lines. The results of the current study increase the current understanding of the function of miRs in the upstream regulation of p53. In addition, these results indicate that targeting mutant p53 through overexpression of miR-600 is a promising therapeutic strategy for the treatment of CRCs bearing p53 mutations.


The present study was supported by the Zhejiang Province Natural Science Foundation of China (grant nos. LY15H160057 and LY17H160056), the National Natural Science Foundation of China (grant no. 81672385) and Wenzhou Science and Technology Bureau Program (grant no. Y20140667).


1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–197. doi: 10.1055/s-0029-1242458. [PMC free article] [PubMed] [Cross Ref]
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. doi: 10.1002/ijc.25516. [PubMed] [Cross Ref]
3. Boyle P, Langman J. ABC of colorectal cancer: Epidemiology. BMJ. 2000;321:805–808. doi: 10.1136/bmj.321.7264.805. [PMC free article] [PubMed] [Cross Ref]
4. Lech G, Slotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol. 2016;22:1745–1755. doi: 10.3748/wjg.v22.i5.1745. [PMC free article] [PubMed] [Cross Ref]
5. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609–622. doi: 10.1016/j.cell.2009.04.050. [PMC free article] [PubMed] [Cross Ref]
6. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107. doi: 10.1101/cshperspect.a001107. [PMC free article] [PubMed] [Cross Ref]
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310. doi: 10.1038/35042675. [PubMed] [Cross Ref]
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53. doi: 10.1126/science.1905840. [PubMed] [Cross Ref]
9. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 2003;100:8424–8429. doi: 10.1073/pnas.1431692100. [PubMed] [Cross Ref]
10. Milner J, Medcalf E. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65:765–774. doi: 10.1016/0092-8674(91)90384-B. [PubMed] [Cross Ref]
11. Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol Cell Biol. 1991;11:12–19. doi: 10.1128/MCB.11.1.12. [PMC free article] [PubMed] [Cross Ref]
12. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107. doi: 10.1101/cshperspect.a001107. [PMC free article] [PubMed] [Cross Ref]
13. Hermeking H. MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613–626. doi: 10.1038/nrc3318. [PubMed] [Cross Ref]
14. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23:862–876. doi: 10.1101/gad.1767609. [PubMed] [Cross Ref]
15. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010;38:689–699. doi: 10.1016/j.molcel.2010.05.027. [PMC free article] [PubMed] [Cross Ref]
16. Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol. 2011;3:44–50. doi: 10.1093/jmcb/mjq040. [PMC free article] [PubMed] [Cross Ref]
17. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2009;16:23–29. doi: 10.1038/nsmb.1533. [PubMed] [Cross Ref]
18. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: The feedback loop. Cell Cycle. 2009;8:712–715. doi: 10.4161/cc.8.5.7753. [PubMed] [Cross Ref]
19. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 2008;14:8080–8086. doi: 10.1158/1078-0432.CCR-08-1422. [PMC free article] [PubMed] [Cross Ref]
20. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Jr, Hofmainster C, Alder H, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367–381. doi: 10.1016/j.ccr.2010.09.005. [PMC free article] [PubMed] [Cross Ref]
21. Manfe V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, Lauenborg BT, Odum N, Gniadecki R. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PloS One. 2012;7:e29541. doi: 10.1371/journal.pone.0029541. [PMC free article] [PubMed] [Cross Ref]
22. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi: 10.1016/0092-8674(93)90529-Y. [PubMed] [Cross Ref]
23. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590–610. doi: 10.1016/j.molonc.2012.09.006. [PubMed] [Cross Ref]
24. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–864. doi: 10.1038/nrc3166. [PMC free article] [PubMed] [Cross Ref]
25. Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: Profiling, signatures and clinical implications. Genome Med. 2013;5:111. doi: 10.1186/gm516. [PMC free article] [PubMed] [Cross Ref]
26. Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML, Kung HF. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 2011;17:709–716. doi: 10.2119/molmed.2011.00008. [PMC free article] [PubMed] [Cross Ref]
27. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007;46:200–208. doi: 10.1002/hep.21668. [PubMed] [Cross Ref]
28. Li XL, Zhou J, Chen ZR, Chng WJ. P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015;21:84–93. doi: 10.3748/wjg.v21.i1.84. [PMC free article] [PubMed] [Cross Ref]
29. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell. 2014;54:960–974. doi: 10.1016/j.molcel.2014.04.024. [PMC free article] [PubMed] [Cross Ref]
30. Lenfert E, Maenz C, Heinlein C, Jannasch K, Schumacher U, Pantel K, Tolstonog GV, Deppert W, Wegwitz F. Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice. Int J Cancer. 2015;136:E521–E533. doi: 10.1002/ijc.29186. [PubMed] [Cross Ref]
31. Ji L, Xu J, Liu J, Amjad A, Zhang K, Liu Q, Zhou L, Xiao J, Li X. Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway. J Biol Chem. 2015;290:11729–11740. doi: 10.1074/jbc.M115.639351. [PMC free article] [PubMed] [Cross Ref]
32. Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, et al. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest. 2014;124:1069–1082. doi: 10.1172/JCI67280. [PMC free article] [PubMed] [Cross Ref]
33. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle. 2008;7:1870–1879. doi: 10.4161/cc.7.12.6161. [PubMed] [Cross Ref]
34. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006;25:304–309. [PubMed]
35. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217–236. doi: 10.1038/nrd4236. [PubMed] [Cross Ref]
36. He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–531. doi: 10.1038/nrg1415. [PubMed] [Cross Ref]
37. Zhu H, Mao Q, Lin Y, Yang K, Xie L. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells. Med Oncol. 2011;28:S381–S387. doi: 10.1007/s12032-010-9679-9. (Suppl 1) [PubMed] [Cross Ref]
38. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, Xie LP. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 2013;11:22. doi: 10.1186/1477-7819-11-22. [PMC free article] [PubMed] [Cross Ref]
39. Cohen M, Wuillemin C, Irion O, Bischof P. Regulation of MMP-9 by p53 in first trimester cytotrophoblastic cells. Hum Reprod. 2008;23:2273–2281. doi: 10.1093/humrep/den264. [PubMed] [Cross Ref]
40. Martelli M, Campana A, Bischof P. Secretion of matrix metalloproteinases by human endometrial cells in vitro. J Reprod Fertil. 1993;98:67–76. doi: 10.1530/jrf.0.0980067. [PubMed] [Cross Ref]
41. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: Implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res. 2006;4:803–810. doi: 10.1158/1541-7786.MCR-06-0201. [PubMed] [Cross Ref]
42. Nawrocki-Raby B, Gilles C, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, Foidart JM, Van Roy F, Birembaut P. E-cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol. 2003;163:653–661. doi: 10.1016/S0002-9440(10)63692-9. [PubMed] [Cross Ref]
43. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers-E-cadherin, beta-catenin, APC and Vimentin-in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48:997–1006. doi: 10.1016/j.oraloncology.2012.05.011. [PubMed] [Cross Ref]
44. Roger L, Jullien L, Gire V, Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 2010;123:1295–1305. doi: 10.1242/jcs.061002. [PubMed] [Cross Ref]
45. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32:3286–3295. doi: 10.1038/onc.2012.334. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications